Valion Bio, Inc.
VBIO institutional ownership changes in Q3 2026: 2 institutions opened or added positions, 0 trimmed or exited. VBIO (Valion Bio, Inc.) is held by 2 institutional investors as of Q3 2026. Top institutional shareholders: UBS Group AG ($25,334), Danske Bank A/S ($3). Institutions were buying, on balance.
No verdict yet — fewer than 2 funds hold VBIO.
Top Holders
| Insider | Trade | Traded |
|---|---|---|
| Wolf Lisa G | Tax 2 sh | |
| Wolf Lisa G | Exercise 4 sh | |
| Wolf Lisa G | Exercise 92 sh | |
| Handley Michael K | Exercise 2K sh |
| Filer | Stake | Filed |
|---|---|---|
| 3i, LP | 9.9% | |
| 3i, LP | 9.9% | |
| 3i, LP | 9.9% | |
| 3i, LP | 9.9% |
VBIOValion Bio, Inc.Continue exploring
Questions investors ask about VBIO
Who owns VBIO?
2 institutional investors held VBIO on September 30, 2026, led by UBS Group AG ($25,334) and Danske Bank A/S ($3).
How many hedge funds hold VBIO?
2 institutional investors reported VBIO in their 13F filings for the quarter ended September 30, 2026, $25,337 in all.
Are institutions buying or selling VBIO?
Buying, on balance. In Q3 2026, 2 institutions opened or added to positions in VBIO and 0 institutions trimmed or exited.
Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer